Meet our Scientific Advisory Board

Established shortly after Antibe’s founding in 2009, our Scientific Advisory Board is comprised of senior scientists and physicians working in inflammation science, gastroenterology, pharmacology and cardiology.

Professor, Biological Sciences & Vice President of Research (Interim)  University of Calgary, Canada

 

Dr. Buret is a professor and scientist focused on infectious and inflammatory disorders of the pulmonary system and gastrointestinal tract.

 

A professor of biological sciences at the University of Calgary for 25 years, he was recently appointed Vice President of Research (Interim) for the university.

 

PhD Pathophysiology of Infectious Diseases  University of Calgary, Canada
Postdoctoral studies at the University of Newcastle, Australia, and the University of Calgary

BSc University of Neuchatel, Switzerland

Co-founder of the renowned Inflammation Research Network at the University of Calgary, Dr. Buret has received numerous teaching and research awards. He has also been inducted into the Order of the University of Calgary, the institution’s top honor.
 

“We need better treatments for inflammation—solutions that don’t put the digestive system at risk.”

Professor Emeritus, Molecular and Medical Pharmacology  University of California Los Angeles School of Medicine, USA

Known as the father of Viagra, Dr. Ignarro’s research focuses on nitric oxide’s role in cardiovascular function. His career also includes roles at the National Institutes of Health and Ciba-Geigy (now Novartis).

He is founder and has been editor-in-chief of Nitric Oxide Biology and Chemistry (Elsevier).

 

PhD Pharmacology  University of Minnesota, USA
Postdoctoral studies at the National Institutes of Health, USA

Member

American Academy of Arts and Sciences
National Academy of Sciences, USA

Dr. Ignarro was awarded the Nobel Prize in Physiology or Medicine for identifying the first gasotransmitter, nitric oxide. He is also the recipient of the Basic Research Prize from the American Heart Association.
 

“John Wallace’s insight into hydrogen sulfide’s anti-inflammatory potential is destined to change how we treat pain.”

Professor of Pharmacology  School of Medicine, University of Naples, Federico II, Italy

Dr. Cirino is recognized worldwide for his research into nitric oxide and hydrogen sulfide, and the roles these gasotransmitters play in cardiovascular function, lung inflammation, and erectile dysfunction.

He is Senior Editor for the British Journal of Pharmacology, the Editor of both Vascular Pharmacology and the Journal of Toxicological and Pharmacological Methods. He is the former Dean of Pharmacy at the University of Naples.

 
 

PhD Pharmacology  University of Naples, Italy
Postdoctoral fellow of Biogen (USA) at the University of Bath, UK

Fellow
British Pharmacological Society
Royal Society of Biology, UK

Member
British Pharmacological Society
Italian Society of Pharmacology

 

Dr. Cirino is a leading researcher in inflammation pharmacology, with more than 300 peer-reviewed articles and several book chapters.
 

“Delving deeper into corticosteroids has reinforced my view that there must be a safer way to tackle unwanted inflammation.”

Professor, Pathology and Director, Comparative Pathology and Medicine; Co-Director, Program in Mucosal Immunology, Allergy, & Vaccine Development  University of California at San Diego, Chiba Medical School, USA

As a veterinarian, professor, and scientist, Dr Ernst’s research focuses on translating the immunobiology of inflammation into new and improved medical treatments, especially those addressing infections and inflammation of the digestive tract.

Dr. Ernst is a board trustee of AAALAC, an not-for-profit organization that promotes the humane treatment of animals in science.

 
 

DVM (Doctor of Veterinary Medicine)  University of Guelph, Canada
PhD Mucosal Immunology  McMaster University, Canada
Postdoctoral studies at McMaster University, Canada
MSc Epidemiology  University of Guelph, Canada

Dr Ernst defined many unique aspects of mucosal immunology in the gastrointestinal tract and has made significant discoveries related to the role of the microbiota in colitis. He was the first to identify two novel receptors for H. pylori and Gram negative bacteria and their connection to inflammation, oxidative stress and DNA damage.

 “In studying the microbiome, one can see the deep roots underlying the biological roles of hydrogen sulfide.”

Professor and Head, Dept. of Experimental and Translational Medicine, Scientific Director, Division of Medicine  University College London, UK

Dr. Gilroy’s research focuses on the molecular and biochemical pathways that regulate and resolve acute immune reactions and inflammation, with the purpose of developing new therapeutics.

He has held the posts of Career Development Fellow and Senior Research Fellow under the Wellcome Trust.

 

PhD Pharmacology  William Harvey Research Institute, University of London, UK
Postdoctoral research at the University of Houston, USA, and Academia Sinica, Taiwan

Dr. Gilroy is a recipient of the Novartis Award from the British Pharmacological Society, and the Bayer International Young Investigator Award for Aspirin Research. He studied under Sir John Vane (Nobel Laureate) at Wellcome Research Laboratories, UK.

“The identification of hydrogen sulfide’s role in resolving inflammation is a major advance in a field that has seen little therapeutic progress in the last 50 years.”

 

Professor Emeritus, Medicine and Gastroenterology  McMaster University, Canada

Dr. Hunt’s research has been primarily in the upper gastrointestinal tract and focuses on acid-related disorders. His work established the worldwide template for pharmacological acid control in the treatment of these conditions.

He has over 37,000 citations from more than 400 papers and has served on the editorial boards of more than 19 scientific journals. He has authored or edited 12 books and numerous chapters on gastrointestinal diseases. Dr. Hunt is a former President of the Canadian Association of Gastroenterology.

 
 

MB ChB (Medical Degree)  University of Edinburgh, UK
Residency at Royal Free, Central and Middlesex Hospitals London, UK

Fellow
American Gastroenterology Association
Canadian Association of Gastroenterology
Royal College of Physicians (London, Edinburgh and Canada)

Master
American College of Gastroenterology
World Gastroenterology Association

Dr. Hunt’s awards include the Gilbert Blane Medal of the Royal Colleges of Physicians and Surgeons of London, and the Bockus Medal of the World Gastroenterology Association. He has also been inducted into the McMaster University Community of Distinction.
 

“Antibe is building an important new drug platform that will serve a large and serious unmet medical need.”

Department Head and Professor, Pharmacology, Therapeutics and Biomedical Sciences  University of São Paulo, Brazil
Professor, Pharmacology  School of Medical Sciences, State University of Campinas and Camilo Castelo Branco University, Brazil

As a medical doctor and scientist, Dr. de Nucci’s research focuses on the pharmacology of inflammation and cardiovascular disease.

He founded the Cartesius Analytical Unit, an organization that provides drug quality reviews for the licensing of generic medications in Brazil. He also established the Galeno Research Center for clinical trials.


MD  Medical School of Ribeirão Preto, University of São Paulo, Brazil
PhD Pharmacology  University of London, UK
Postdoctoral studies at Wellcome Research Laboratories, UK

Member
Brazilian Academy of Medicine

Dr. de Nucci has published more than 500 scientific papers and other scientific works. He studied under Sir John Vane (Nobel Laureate) and Sir Salvador Moncada at Wellcome Research Laboratories in the UK.

“The promise of hydrogen sulfide is profound.”

President  University of Texas Southwestern Medical Center, USA

A medical doctor, scientist, and senior university administrator, Dr. Podolsky holds two Distinguished Chairs at the University of Texas Medical School. His clinical research focuses on the diagnosis and treatment of gastroenterological diseases.

He is a member of the board of directors of Agilent Technologies and former member of the board of directors of GlaxoSmithKline. He is former President of the American Gastroenterological Association and former Editor-in-Chief of Gastroenterology, the leading journal in the field.

 

MD  Harvard Medical School, USA
Residency and Fellowship at Massachusetts General Hospital, USA

Member
American Association of Physicians
American Federation of Clinical Research
American Gastroenterological Association
American Society for Clinical Investigation
National Academy of Medicine, USA

 
Dr. Podolsky is a recipient of the Julius Friedenwald Medal and the Distinguished Achievement Award, both from the American Gastroenterological Association. He is also a past recipient of the Merit Award from the National Institutes of Health.
 

“The opioid crisis has vastly increased the need and urgency for safer, non-addictive pain therapeutics.”

Alfred Gilman Professor and Vice Chairman, Pharmacology and Cardiology, and Director, Vascular Biology & Therapeutics  Yale School of Medicine, USA

Dr. Sessa’s research focuses on the endothelium as a key player in cardiovascular disease and atherosclerosis.

He has chaired study sections at the National Institutes of Health, and for the American Heart Association. Dr. Sessa has served as President of the North American Vascular Biology Organization and has been an editor for several cardiovascular journals.

 

PhD Pharmacology  New York Medical College, USA
Postdoctoral at the William Harvey Research Institute, UK, and the University of Virginia School of Medicine, USA

Dr Sessa is an inaugural recipient of the Merit Award from the American Heart Association. He has also received the highest award of distinction from the North American Vascular Biology Organization in recognition of his work on the production and regulation of nitric oxide in the vasculature.
 

“As we age, the body’s inflammation responses become increasingly counterproductive. Antibe’s research suggests that hydrogen sulfide can play a significant protective role.”

Professor and Canada Research Chair, Paediatrics, Microbiology, Laboratory Medicine and Pathobiology, Nutritional Sciences & Dentistry  The Hospital for Sick Children, University of Toronto, Canada

Dr. Sherman’s research focuses on the factors influencing onset and progression of inflammatory bowel disease.

He is the former Scientific Director of the Institute of Nutrition, Metabolism and Diabetes at the Canadian Institutes for Health Research. He is also former President of the Canadian Association of Gastroenterology and former President of the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition. Dr. Sherman completed a Research Fellowship at Walter Reed Army Institute of Research, Washington, DC.

 

MD  University of Toronto Medical School, Canada
Residency at the University of California, USA

Fellow
Canadian Association of Gastroenterology, Canada

Dr. Sherman is a recipient of the Distinguished Service Award and the Physician Research Award for Career Excellence from the Canadian Association of Gastroenterology. Hepatology, and Nutrition.
 

“Particularly in children, pain management presents clinicians with a challenging set of trade-offs. Antibe’s research suggests that there are better alternatives on the horizon.”

Attention

This is an external link. Click “OK” to continue.

CANCEL OK